Frederick L. Locke, MD, chair in the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer ...
4A10, a monoclonal antibody targeting interleukin-7 receptor alpha (IL-7Rα; CD127), has received fast track designation from the FDA for the treatment of patients with relapsed or refractory acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback